ABOS — Acumen Pharmaceuticals Share Price
Last Trade - 00:00Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The Company's ACU193 is a humanized monoclonal antibody that selectively targets anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques.
Directors
- Last Annual
- Last Interim
- Incorporated
- January 4th, 1996
- Public Since
- January 1st, 1970
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 1
- Address
- 4435 NORTH FIRST STREET, SUITE 360, LIVERMORE, 94551
- Web
- http://www.acumenpharm.com/
- Phone
- +1 9253688508
- Auditors
Latest News for ABOS
Upcoming events for ABOS
Similar to ABOS
4D MOLECULAR THERAPEUTICS ORD
NASDAQ Global Select Market
ABCELLERA BIOLOGICS ORD
NASDAQ Global Select Market
ABSCI ORD
NASDAQ Global Select Market
ACADIA PHARMACEUTICALS ORD
NASDAQ Global Select Market
ACHILLES THERAPEUTICS ADS
NASDAQ Global Select Market
FAQ
As of Today at 19:55 UTC, shares in Acumen Pharmaceuticals are trading at $15.41. This share price information is delayed by 15 minutes.
Shares in Acumen Pharmaceuticals last closed at $15.41 and the price had moved by over the past 365 days. In terms of relative price strength the Acumen Pharmaceuticals share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Acumen Pharmaceuticals does not currently pay a dividend.
Acumen Pharmaceuticals does not currently pay a dividend.
Acumen Pharmaceuticals does not currently pay a dividend.
To buy shares in Acumen Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $15.41, shares in Acumen Pharmaceuticals had a market capitalisation of $0.00m.
Here are the trading details for Acumen Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABOS
Based on an overall assessment of its quality, value and momentum Acumen Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acumen Pharmaceuticals. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $15.41, shares in Acumen Pharmaceuticals were trading -8.04% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acumen Pharmaceuticals.
We do not have data on Acumen Pharmaceuticals' directors
We do not have data on Acumen Pharmaceuticals' shareholders